ABACAVIR SULFATE AND LAMIVUDINE (abacavir and lamivudine) by Molecular Devices is nucleoside reverse transcriptase inhibitors [moa]. Approved for human immunodeficiency virus type 1 (hiv-1) infection, combination with other antiretroviral agents for the treatment of hiv-1 infection. First approved in 2024.
Drug data last refreshed 20h ago
Nucleoside Reverse Transcriptase Inhibitors
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Worked on ABACAVIR SULFATE AND LAMIVUDINE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites
Abacavir and Lamivudine PK in Children
A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)